The sugar content of food and drinks played an unseen role in the Covid-19 death toll, says engagement specialist Peter van der Werf.
He says food companies need to accelerate plans to take sugar out of their products, as it is a major cause of obesity and diabetes, which has made people more vulnerable to dying from the coronavirus.
Research by the UK’s National Health Service shows that one-third of the people who died from Covid-19 had either Type 1 or Type 2 diabetes, a condition in which the body can’t make its own insulin, requiring lifelong treatment.1
The coronavirus is known to more adversely affect people with underlying health conditions as it causes the immune system to go haywire, leading to a higher death toll among diabetics, along with the elderly and infirm. More than 400 million people in the world now have diabetes, or one in ten of the adult population, while one-third of all US adults are obese.2
Aside from the health issues, the negative impact on the performance of a company using sugar in its processes can be significant. The costs associated with obesity include increased health care expenses, decreased productivity and premature deaths. Because of this, food and beverage companies face regulatory, reputational, legal and market risks.
Examples include governments in both high- and lower-income countries that are introducing a sugar tax, or are restricting advertising of less-healthy products to children. Regulation is increasing over the use of health and nutrition claims, while food labelling requirements are being strengthened. Ultimately, companies that do not adjust to changing dietary preferences may lose market share, revenues and profits.
“Sugar has contributed strongly to the current global obesity crisis, and to the onset of diabetes, given its presence in almost all packaged food or drinks,” says Van der Werf, who focuses on engagement with the sector.
“The economic costs of obesity are clear; USD 2 trillion annually, or nearly 3% of global GDP. It is estimated that obesity, along with smoking and armed violence, is one of the top three social burdens induced by humans.”
“Sugar has a direct link with one-third of the Covid-19 fatalities as these were associated with diabetes. In the US, researchers found that people with diabetes who contracted Covid-19 were twice as likely to die within a week than non-diabetic patients.”
Robeco is concluding a three-year engagement program with eight companies in the food and beverage industry that aimed to encourage them to use less sugar in their products.
“The engagement called on them to speed up product reformulation and innovation to ensure a successful business model in the long run, and all eight companies have made good progress with this,” Van der Werf says. “This has led to a 10% drop in the sugar content on average.”
“But when it comes to communicating this, many companies initially opted for ‘stealth reformulation’ – by only mentioning on the back of the packet that the product’s sugar content has been reduced. This is due to the negative reaction that their consumers often give to prominent announcements of sugar reduction, resulting in a sharp drop in sales.”
“We also remain concerned about the large volumes of sugar that are still sold to consumers as part of processed foods, especially as this pertains to some of the flagship legacy products that remain a very important cornerstone of their product portfolios.”
Innovation has proved key in producing more nutritious foods that are increasingly demanded by a more health-conscious society, he says. The companies that don’t reformulate face a backlash for the ‘social risks of sugar’ in the same way that tobacco eventually became socially unacceptable to the mass market.
“Not all companies under engagement have made the level of progress on innovation management that we expect from the food industry,” Van der Werf says. “The leading companies have made larger shifts in strategy towards healthy product categories, which we think provides the best future-proof strategy when it comes to minimizing the social risk of sugar.”
“Other companies indicated that in general, having healthy attributes are an important consideration for any new product launch. However, some remain heavily vested in high-sugar carbonated soft drinks, or are expanding into energy drinks with a high sugar content. Or they are continuing to focus on highly processed food products which in most cases need sugar to make them palatable for consumers.”
With a much greater focus on the fragility of human health brought about by the coronavirus pandemic, Van der Werf says this may now accelerate moves to lower the sugar content of food and drinks.
“The Covid-19 pandemic has further strengthened our view that obesity is an important global health risk with a significant economic impact,” he says.
“The food industry will be held accountable for its future role in marketing high-sugar products for consumers who are not able to make dietary choices that prevent obesity. This obesity risk therefore continues to be a long-term overhang for the industry.”
Also read: food sustainability
The information contained on these pages is for marketing purposes and solely intended for Qualified Investors in accordance with the Swiss Collective Investment Schemes Act of 23 June 2006 (“CISA”) domiciled in Switzerland, Professional Clients in accordance with Annex II of the Markets in Financial Instruments Directive II (“MiFID II”) domiciled in the European Union und European Economic Area with a license to distribute / promote financial instruments in such capacity or herewith requesting respective information on products and services in their capacity as Professional Clients.
The Funds are domiciled in Luxembourg and The Netherlands. ACOLIN Fund Services AG, postal address: Affolternstrasse 56, 8050 Zürich, acts as the Swiss representative of the Fund(s). UBS Switzerland AG, Bahnhofstrasse 45, 8001 Zurich, postal address: Europastrasse 2, P.O. Box, CH-8152 Opfikon, acts as the Swiss paying agent. The prospectus, the Key Investor Information Documents (KIIDs), the articles of association, the annual and semi-annual reports of the Fund(s) may be obtained, on simple request and free of charge, at the office of the Swiss representative ACOLIN Fund Services AG. The prospectuses are also available via the website www.robeco.ch. Some funds about which information is shown on these pages may fall outside the scope of the Swiss Collective Investment Schemes Act of 26 June 2006 (“CISA”) and therefore do not (need to) have a license from or registration with the Swiss Financial Market Supervisory Authority (FINMA).
Some funds about which information is shown on this website may not be available in your domicile country. Please check the registration status in your respective domicile country. To view the RobecoSwitzerland Ltd. products that are registered/available in your country, please go to the respective Fund Selector, which can be found on this website and select your country of domicile.
Neither information nor any opinion expressed on this website constitutes a solicitation, an offer or a recommendation to buy, sell or dispose of any investment, to engage in any other transaction or to provide any investment advice or service. An investment in a Robeco Switzerland Ltd. product should only be made after reading the related legal documents such as management regulations, prospectuses, annual and semi-annual reports.